Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) rose 4.8% on Thursday . The company traded as high as $9.23 and last traded at $9.13. Approximately 151,634 shares were traded during trading, a decline of 88% from the average daily volume of 1,229,962 shares. The stock had previously closed at $8.71. Analyst Upgrades and Downgrades […]
A phase 1 gene editing trial in patients with heterozygous familial hypercholesterolemia and atherosclerotic CVD was paused after abnormal lab results were seen.
Verve Therapeutics (NASDAQ:VERV) Price Target Lowered to $40 00 at Stifel Nicolaus theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) insider Joan Nickerson sold 1,514 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $8.24, for a total transaction of $12,475.36. Following the transaction, the insider now directly owns 8,659 shares of the […]
Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT.